ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

URGN vs MLYS // OPERATING MARGIN

UroGen Pharma Ltd. (NASDAQ) VS. Mineralys Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: URGN 0 — MLYS 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (URGN VS. MLYS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC URGN MLYS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 88.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -28.40% -6.60 MLYS /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.94% -7.58% -2.36 MLYS /fcf-yield <GO>
Operating Margin ACTIVE -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 21.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 29.7 36.9 -7.20 MLYS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.60B $1.61B -$7.9M MLYS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR URGN REV MLYS REV URGN GROSS % MLYS GROSS % URGN FCF MLYS FCF
FY 2025 $109.8M $477.7M 88.7% — -$162.7M -$142.4M
FY 2024 $90.4M $538.7M 90.2% — -$97.1M -$166.3M
FY 2023 $82.7M $237.0M — — -$76.4M -$81.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
URGN // BETA —
MLYS // BETA —